Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pecorelli

Showing results (61-70 of 160) with videos related to

Pageof 16
Sort By:
Gynecologic Oncology|May 24, 2001
Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervixA D Santin, A Ravaggi, S Bellone, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 6, 1999
Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative GroupA Pawinski, S Tumolo, G Hoesel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
A new standard of care for treatment of ovarian cancerM J Piccart, A Du Bois, M E Gore, et al.
American Journal of Obstetrics and Gynecology|September 19, 2000
In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancerA D Santin, P L Hermonat, A Ravaggi, et al.
British Journal of Cancer|February 22, 2002
Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancerA D Santin, S Bellone, A Ravaggi, et al.
Minerva Ginecologica|May 29, 2002
Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancerA D Santin, S Bellone, L J Underwood, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 1, 1995
Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccineA.D. Santin, G.R. Ioli, J.C. Hiserodt, et al.
Cancer|November 15, 1995
Replacement therapy for breast cancer survivors. A pilot studyP J DiSaia, E A Grosen, F Odicino, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group studyS Pecorelli, H C Wagenaar, I B Vergote, et al.
American Journal of Obstetrics and Gynecology|February 1, 1996
Development and characterization of an interleukin-2-transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex moleculesA D Santin, G R Ioli, J C Hiserodt, et al.
Pageof 16

Showing results (61-70 of 160) with videos related to

Sort By:
Pageof 16
Gynecologic Oncology|May 24, 2001
Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervixA D Santin, A Ravaggi, S Bellone, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 6, 1999
Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative GroupA Pawinski, S Tumolo, G Hoesel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
A new standard of care for treatment of ovarian cancerM J Piccart, A Du Bois, M E Gore, et al.
American Journal of Obstetrics and Gynecology|September 19, 2000
In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancerA D Santin, P L Hermonat, A Ravaggi, et al.
British Journal of Cancer|February 22, 2002
Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancerA D Santin, S Bellone, A Ravaggi, et al.
Minerva Ginecologica|May 29, 2002
Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancerA D Santin, S Bellone, L J Underwood, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 1, 1995
Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccineA.D. Santin, G.R. Ioli, J.C. Hiserodt, et al.
Cancer|November 15, 1995
Replacement therapy for breast cancer survivors. A pilot studyP J DiSaia, E A Grosen, F Odicino, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group studyS Pecorelli, H C Wagenaar, I B Vergote, et al.
American Journal of Obstetrics and Gynecology|February 1, 1996
Development and characterization of an interleukin-2-transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex moleculesA D Santin, G R Ioli, J C Hiserodt, et al.
Pageof 16